FIELD: medicine.
SUBSTANCE: invention relates to medicines, particularly to the use of chimeric peptide VP-22_p16INK4a for epithelial and mesenchymal malignant neoplasms treatment. The claimed chimeric peptide VP-22_p16INK4a contains two amino acid sequences. The first sequence comprises inhibitor of cycline kinases as active fragment p16INK4a as therapeutic agent and the second sequence comprises peptide VP22 of herpes simplex virus as carrier agent to deliver cycline kinase inhibitor into target cells.
EFFECT: enlarging the application range of medicine.
9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PEPTIDE FOR TREATING BREAST FIBROADENOMA | 2010 |
|
RU2456297C1 |
| CHIMERIC PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | 2010 |
|
RU2435783C1 |
| CHIMERIC PROTEIN FOR MALIGNANT LYMPHOMA TREATMENT | 2004 |
|
RU2297241C2 |
| POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
| PEPTIDES OBTAINED FROM p16 FOR PREVENTION AND TREATMENT OF HPV-ASSOCIATED TUMOURS AND OTHER TUMOURS EXPRESSING p16 | 2012 |
|
RU2626542C2 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| METHOD FOR NEOPLASTIC DISEASE DETECTION ON THE BASIS OF SOLUBILISED PHYSIOLOGICAL SAMPLE | 2004 |
|
RU2405158C2 |
| HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF | 2014 |
|
RU2679500C2 |
| USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS | 2014 |
|
RU2702428C2 |
| METHOD FOR ACTIVATING CYTOTOXIC T-LYMPHOCYTES IN A POPULATION OF BLOOD MONONUCLEAR CELLS USING MEMBRANE VESICLES OBTAINED FROM GENETICALLY MODIFIED TUMOR CELLS OF M14 MELANOMA WITH OVEREXPRESSION OF INTERLEUKIN 2 | 2022 |
|
RU2790867C1 |
